High potency active pharmaceutical ingredients (HPAPIs) account for over 50% of today’s small molecule new chemical entity (NCE) drug pipeline. Although they represent a revolutionary pharmaceutical advancement in the areas of oncology treatments and personalized medicine, their development and manufacturing carry inherent risks due to their toxicity levels.
This webinar covers key considerations in developing and manufacturing HPAPIs, including product containment strategies, personnel protection needs, and cross-contamination risks.
Specific webinar key takeaways include:
Additionally, viewers will explore how an experienced CDMO partner like Thermo Fisher Scientific can help provide the right knowledge, infrastructure, and commitment to safety that’s needed to help biopharma companies overcome various industry challenges related to HPAPI development and manufacturing.
Watch the on-demand webinar to learn more.